| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9408979 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(2 months ago) | |
| US9526844 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(2 months ago) | |
| US9233211 | SANOFI US SERVICES | Relating to a pen-type injector |
Mar, 2024
(2 months ago) | |
| US9775954 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(2 months ago) | |
| US9604008 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(2 months ago) | |
| US8603044 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(2 months ago) | |
| US9610409 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(2 months ago) | |
| US9827379 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(2 months ago) | |
| US8556864 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Mar, 2024
(a month ago) | |
| US9011391 | SANOFI US SERVICES | Pen-type injector |
Mar, 2024
(a month ago) | |
| US8992486 | SANOFI US SERVICES | Pen-type injector |
Jun, 2024
(a month from now) | |
| US9604009 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9533105 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9623189 | SANOFI US SERVICES | Relating to drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US9561331 | SANOFI US SERVICES | Drive mechanisms suitable for use in drug delivery devices |
Aug, 2024
(3 months from now) | |
| US8512297 | SANOFI US SERVICES | Pen-type injector |
Sep, 2024
(4 months from now) | |
| US8679069 | SANOFI US SERVICES | Pen-type injector |
Apr, 2025
(11 months from now) | |
| US7918833 | SANOFI US SERVICES | Pen-type injector |
Sep, 2027
(3 years from now) | |
| US9345750 | SANOFI US SERVICES | Long-acting formulations of insulin |
May, 2031
(7 years from now) | |
| US10369291 | SANOFI US SERVICES | Mechanism for a drug delivery device |
Sep, 2035
(11 years from now) | |
Toujeo Max Solostar is owned by Sanofi Us Services.
Toujeo Max Solostar contains Insulin Glargine Recombinant.
Toujeo Max Solostar has a total of 20 drug patents out of which 10 drug patents have expired.
Expired drug patents of Toujeo Max Solostar are:
- US9408979
- US9526844
- US9233211
- US9775954
- US9604008
- US8603044
- US9610409
- US9827379
- US8556864
- US9011391
Toujeo Max Solostar was authorised for market use on 25 February, 2015.
Toujeo Max Solostar is available in solution;subcutaneous dosage forms.
Toujeo Max Solostar can be used as improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve, improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve, improvement in glycemic control in diabetes mellitus patients.
The generics of Toujeo Max Solostar are possible to be released after 16 September, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 25, 2018 |
| New Patient Population(NPP) | Nov 26, 2022 |
Drugs and Companies using INSULIN GLARGINE RECOMBINANT ingredient
Market Authorisation Date: 25 February, 2015
Treatment: Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a rotating drive sleeve; Improvement in glycemic control in diabetes mellitus patients by use of a pen injec...
Dosage: SOLUTION;SUBCUTANEOUS
TOUJEO MAX SOLOSTAR family patents
